Skip to Content

Swiss drugmaker Novartis to spin off generics unit Sandoz


GENEVA (AP) — Swiss pharmaceuticals company Novartis says it plans to spin off its generics subsidiary Sandoz, which generated nearly $10 billion in revenue last year. The Basel-based powerhouse said Thursday that it wants to focus on its core innovation business built around therapeutics and technology such as gene and cell therapy. Sandoz was one of two Swiss companies that merged more than a quarter-century ago to form Novartis, and the brand later become a division focused on generic drugs. Novartis makes a vast array of drugs including cancer treatment Gleevec and Diovan for hypertension. Its shares initially rose after the announcement then headed lower.

Article Topic Follows: AP National Business

Jump to comments ↓

Author Profile Photo

Associated Press


KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content